Insider Sell: Protagonist Therapeutics
5:22PM ET 12/23/2021 MT NewswiresDinesh V Patel, Director, President and CEO, on December 21, 2021, sold 15,000 shares in Protagonist Therapeutics (PTGX) for $482,171. Following the Form 4...
Quotes Snapshot > PTGX
Protagonist Therapeutics Inc PTGX:NASDAQ
Last Price$28.42NASDAQ Previous Close - Last Trade as of 3:57PM ET 1/26/22
Today's Change-0.38(1.32%)
Bid (Size)$13.01 (1)
Ask (Size)$39.99 (1)
Day Low / High$28.00 - 30.34
Volume635.0 K
Read more news Recent News
Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
5:26PM ET 12/02/2021 MT NewswiresProtagonist Therapeutics (PTGX) said Thursday it has chosen PN-235 as the final candidate for all clinical studies in multiple indications as part of its...
Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditary Hemochromatosis Treatment
11:05AM ET 11/15/2021 MT NewswiresProtagonist Therapeutics (PTGX) said Monday that results from a study to evaluate rusfertide as an investigational drug to treat hereditary...
--JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps Market Outperform Rating
9:05AM ET 11/15/2021 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow
3:02PM ET 1/11/2022 Seeking AlphaProtagonist Therapeutics (PTGX) Investor Presentation - Slideshow
3:23PM ET 12/09/2021 Seeking AlphaWall Street Breakfast: What Moved Markets
7:47AM ET 10/16/2021 Seeking AlphaProtagonist Therapeutics: How To Buy The Dip
6:14PM ET 9/30/2021 Seeking AlphaCompany Profile
Business DescriptionProtagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. View company web site for more details
| Address | 7707 Gateway Boulevard Newark, California 94560-1160 |
| Phone | +1.510.474.0170 |
| Number of Employees | 64 |
| Recent SEC Filing | 12/23/2021 4 |
| President, Chief Executive Officer & Director | Dinesh V. Patel |
| Chief Financial Officer | Donald A. Kalkofen |
| Vice President-Technology | Mark L. Smythe |
| Chief Scientific Officer | David Y. Liu |
Company Highlights
| Price Open | $29.28 |
| Previous Close | $28.42 |
| 52 Week Range | $12.80 - 50.54 |
| Market Capitalization | $1.4 B |
| Shares Outstanding | 47.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/09/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$2.41 |
| Beta vs. S&P 500 | N/A |
| Revenue | $30.9 M |
| Net Profit Margin | -440.88% |
| Return on Equity | -35.08% |
Analyst Ratings as of 10/11/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |